Group 1: Clinical Trial Results - Eli Lilly's TOGETHER-PsO trial showed that 27.1% of participants receiving Taltz and Zepbound achieved complete skin clearance and at least 10% weight loss, compared to 5.8% for Taltz alone, meeting the primary endpoint [2] - The combination of Taltz and Zepbound resulted in a 40% relative increase in the proportion of patients achieving PASI 100 compared to Taltz monotherapy (40.6% vs. 29%) [2] Group 2: Licensing Agreement - CSL Limited entered into an exclusive licensing agreement with Eli Lilly for the development and commercialization of clazakizumab, with an upfront payment of $100 million and potential milestone payments and royalties on global net sales [4] - CSL retains exclusive rights to develop clazakizumab for preventing cardiovascular events in patients with end-stage kidney disease, while Lilly will explore additional indications [5] Group 3: Stock Performance - The stock is currently trading 2.7% below its 20-day simple moving average and 3.2% below its 50-day simple moving average, indicating short-term weakness, but remains 4.3% above its 100-day simple moving average and 17.6% above its 200-day simple moving average, suggesting longer-term strength [7] - The RSI is at 48.22, indicating neutral territory, while the MACD shows bearish pressure with a value of -5.0984 below its signal line of -3.9365 [8]

来源：中国基金报 万亿外资巨头又调仓了！ 根据美国证券交易委员会（SEC）披露，近日资管巨头贝莱德递交了截至2025年12月31日的第四季度持 仓报告（13F）。 根据13F，贝莱德第四季度持仓总市值为5.92万亿美元，环比增长3.67%。去年第四季度，贝莱德投资组 合中新增了247只个股，清仓165只个股。其中，前十大重仓股占总市值30.41%。 具体来看，前五大买入标的为谷歌-A、谷歌-C、礼来、美光（MU.US）、苹果。前五大卖出标的为标 普500ETF-SPDR CALL（SPY.US.CALL）、ServiceNow（NOW.US）、Strategy（MSTR.US）、AT&T （T.US）、Kellanova （K，现已退市）。 "前十大"科技含量较高 增持英伟达、苹果、微软等 根据13F，贝莱德持有的前十大重仓股科技含量较高，具体包括：英伟达（NVDA.US）、苹果 （AAPL.US）、微软（MSFT.US）、亚马逊（AMZN.US）、谷歌-A（GOOGL.US）、博通 （AVGO.US）、谷歌-C（GOOG.US）、META（META.US）、特斯拉（TSLA.US）、礼来 （LLY.US）等 ...

But it's good news for Eli Lilly, too.Novo Nordisk (NVO 2.05%) has struggled over the past year, and the company recently hit another setback when it reported disappointing fourth-quarter results and even worse guidance for fiscal year 2026. The stock price fell by nearly 15% following these developments.However, there are several things to look forward to for Novo Nordisk. One of them is its recent launch of an oral version of its famous weight loss drug, Wegovy. And regarding this product, Novo Nordisk ju ...

Eli Lilly and Company (NYSE:LLY) is included among the 16 Best Dividend Stocks with Rising Payouts. Eli Lilly (LLY) Expands Pipeline with Clazakizumab Agreement, Reuters Reports According to a Reuters report on February 18, Australia’s CSL said it had granted Eli Lilly and Company (NYSE:LLY) certain rights to develop and commercialize clazakizumab, an anti-interleukin-6 monoclonal antibody. In return, CSL will receive an upfront payment of $100 million. CSL will keep exclusive rights to develop and comme ...

Core Insights - The biotech industry experienced significant developments this week, including FDA approvals, clinical trial results, and licensing agreements, indicating a dynamic landscape for investment opportunities and advancements in healthcare [1]. FDA Approvals & Rejections - NRx Pharmaceuticals is on track for FDA approval of NRX-100, with existing clinical data and real-world evidence from over 65,000 patients potentially supporting a New Drug Application (NDA) under Fast Track Designation [2][3]. - Kane Biotech received FDA clearance for its Revyve Antimicrobial Skin and Wound Cleanser, which targets wound bacteria and biofilms, with plans for manufacturing scale-up in 2026 [4][5]. - Johnson & Johnson's RYBREVANT FASPRO received FDA approval for a simplified monthly dosing schedule, enhancing treatment options for patients with advanced non-small cell lung cancer [6][7]. - Spruce Biosciences reported positive feedback from FDA Type B meetings for its enzyme replacement therapy for Sanfilippo syndrome type B, with a targeted BLA filing in Q4 2026 [8][9]. - Moderna's seasonal influenza vaccine submission (mRNA-1010) is under FDA review, with a PDUFA date set for August 5, 2026, aiming for availability in the 2026/2027 flu season [10][11]. - Disc Medicine received a Complete Response Letter (CRL) for its NDA for Biopertin in erythropoietic protoporphyria, citing insufficient correlation with sunlight exposure endpoints [13][14]. - AbbVie and Genentech's combination regimen of VENCLEXTA and Acalabrutinib for chronic lymphocytic leukemia (CLL) received FDA approval, showing a 35% reduction in disease progression risk compared to standard treatment [15][16]. Deals - Theriva Biologics entered an exclusive licensing agreement with Rasayana Therapeutics for SYN-020, receiving a $3 million upfront payment and potential milestone payments totaling up to $38 million [17][18]. - Sensei Biotherapeutics acquired Faeth Therapeutics, expanding its oncology portfolio with the investigational asset PIKTOR, and announced a concurrent private placement of $200 million to advance clinical milestones [19][20]. Clinical Trials - Breakthroughs - Eli Lilly's Taltz and Zepbound combination therapy showed positive results in a Phase 3 trial for plaque psoriasis and obesity, achieving superior outcomes compared to Taltz alone [21][22]. - Zealand Pharma reported positive Phase 1a results for ZP9830, a Kv1.3 channel blocker, demonstrating safety and tolerability in healthy volunteers [23][24]. - Novartis' Remibrutinib met primary endpoints in a Phase 3 trial for chronic inducible urticaria, showing significant response rates compared to placebo [26][27]. - Ocular Therapeutix's AXPAXLI demonstrated superiority over aflibercept in a Phase 3 trial for wet age-related macular degeneration, although stock prices fell due to investor disappointment [28][29]. - Rallybio's RLYB116 Phase 1 study showed promising results for immune platelet transfusion refractoriness, with plans for a Phase 2 trial in 2026 [31][32]. - Teva and Sanofi's Duvakitug Phase 2b trial demonstrated durable efficacy in ulcerative colitis and Crohn's disease, reinforcing the rationale for ongoing Phase 3 programs [35][36]. - Genentech's Gazyva met primary endpoints in a Phase III study for primary membranous nephropathy, showing significant remission rates compared to tacrolimus [38][39].

U.S. Food and Drug Administration (FDA) Commissioner Marty Makary holds up a study from The Lancet during an announcement of the FDA’s intent to phase out the use of petroleum-based synthetic dyes in the nation’s food supply during a press conference at the Department of Health and Human Services in Washington, D.C., U.S., April 22, 2025. REUTERS/Elizabeth FrantzElizabeth Frantz | ReutersA version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news s ...

Eli Lilly and Co. (NYSE:LLY) on Monday shared positive topline results from the Phase 3 LIBRETTO-432 clinical trial for Retevmo (selpercatinib). The trial demonstrated a highly statistically significant improvement in event-free survival for patients with early-stage non-small cell lung cancer. Lung Cancer Trial Shows Benefit The LIBRETTO-432 trial results showed that selpercatinib significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell lung cance ...

efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight[Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open- label Phase 3b clinical trial...]### Lilly to participate in TD Cowen's 46th Annual Health Care Conference[Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice...][More Releases From This Source]## Explore[He ...

Core Insights - Ozempic, a drug by Novo Nordisk, is widely recognized for treating type 2 diabetes and aiding weight loss, being part of the GLP-1 drug class [1] - Eli Lilly has overtaken Novo Nordisk in the GLP-1 market, capturing 60% of the market share compared to Novo's 39% [4] Group 1: Company Performance - Eli Lilly's drugs, Mounjaro and Zepbound, generated over $11 billion in revenue, showcasing triple-digit growth in the recent quarter [5] - Novo Nordisk's semaglutide is marketed as Ozempic for diabetes and Wegovy for obesity, but its market share has declined as Lilly's products gained popularity [4][6] Group 2: Competitive Advantage - Eli Lilly's success is attributed to effective manufacturing and availability of its products, addressing previous shortages of GLP-1 drugs [6] - A head-to-head study demonstrated that Zepbound led to greater weight loss compared to Wegovy, influencing patient and doctor preferences [6] Group 3: Future Prospects - Novo recently launched a Wegovy pill, while Lilly is under regulatory review for an oral weight loss candidate that offers a hassle-free option without dietary restrictions [7]

2026.02．19 当地时间2月18日，礼来公司公布了一项最新研究结果，显示出该公司的减重药替尔泊肽在肥胖合并自 身免疫性疾病方面的潜力。 一项针对274名银屑病患者的后期研究数据显示，使用替尔泊肽与该公司现有生物制剂依奇珠单抗联合 治疗的效果优于单独使用依奇珠单抗的疗效，并且联合治疗可同时实现减轻皮肤症状及体重减轻的双重 效果。 与此同时，随着礼来的口服减重药即将获批，双方在口服减重制剂领域的竞争已经开打。根据一份上周 公布的备案文件，礼来正在为口服减重药大举备货，公司预上市库存规模已达15亿美元，较去年同期的 5.5亿美元大幅增长。 微信编辑 | 雨林 责任编辑：王珂 2026.02．19 数据显示，在治疗36周时，约27.1%接受联合疗法的患者达到了银屑病完全清除的治疗目标，同时实现 10%的体重减轻；而单独使用依奇珠单抗的患者达到治疗目标的比例仅5.8%。 银屑病是一种慢性自身免疫性疾病，会导致皮肤上出现瘙痒、鳞屑斑块。这项研究结果显示了此类减重 药在治疗肥胖合并症方面的潜力，大部分肥胖患者还伴有至少一种与体重相关的合并症。 目前，礼来及主要竞争对手诺和诺德正在多个市场针对多种减重疗法新适应症方面展 ...